|
ViraTree LLC
piv3-gfp virus p323 Piv3 Gfp Virus P323, supplied by ViraTree LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/piv-3/piv3+gfp+virus+p323/pmc07494516-39-0-7 Average 90 stars, based on 1 article reviews
piv3-gfp virus p323 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Promega
interferon induction activity measuring reporter plasmid (piv3 Interferon Induction Activity Measuring Reporter Plasmid (Piv3, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/piv-3/interferon+induction+activity+measuring+reporter+plasmid++piv3/us09145564-277-6-40 Average 90 stars, based on 1 article reviews
interferon induction activity measuring reporter plasmid (piv3 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Glaxo Smith
antibody titre against intramuscular poliovirus type 3 ![]() Antibody Titre Against Intramuscular Poliovirus Type 3, supplied by Glaxo Smith, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/piv-3/live+attenuated+parainfluenza+virus+type+3++piv3++vaccine/pmc06923520-1109-2-21 Average 90 stars, based on 1 article reviews
antibody titre against intramuscular poliovirus type 3 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Boehringer Ingelheim
bhv-1, bvdv, piv-3, brsv live vaccine; m. haemolytica bacterin ![]() Bhv 1, Bvdv, Piv 3, Brsv Live Vaccine; M. Haemolytica Bacterin, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/piv-3/bhv+1++bvdv++piv+3++brsv+live+vaccine/pmc08276037-31-3-10 Average 90 stars, based on 1 article reviews
bhv-1, bvdv, piv-3, brsv live vaccine; m. haemolytica bacterin - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Sanofi
combined rsv, hmpv, piv3 mrna vaccine ![]() Combined Rsv, Hmpv, Piv3 Mrna Vaccine, supplied by Sanofi, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/piv-3/combined+rsv++hmpv++piv3+mrna+vaccine/pmc12197412-15-7-2 Average 90 stars, based on 1 article reviews
combined rsv, hmpv, piv3 mrna vaccine - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Argene Inc
coronavirus (nl63, oc43, khu1, 229e) and parainfluenza (piv1, piv2, piv3, piv4) kit ![]() Coronavirus (Nl63, Oc43, Khu1, 229e) And Parainfluenza (Piv1, Piv2, Piv3, Piv4) Kit, supplied by Argene Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/piv-3/coronavirus++nl63++oc43++khu1++229e++and+parainfluenza++piv1++piv2++piv3++piv4++kit/pmc07185839-50-15-15 Average 90 stars, based on 1 article reviews
coronavirus (nl63, oc43, khu1, 229e) and parainfluenza (piv1, piv2, piv3, piv4) kit - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
ViraTree LLC
piv3–gfp ![]() Piv3–Gfp, supplied by ViraTree LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/piv-3/human+parainfluenza+virus+type+iii++piv3++strain+js/pmc09355872-313-2-22 Average 90 stars, based on 1 article reviews
piv3–gfp - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Biotechnology Information
piv-3 sequence accession numbers ![]() Piv 3 Sequence Accession Numbers, supplied by Biotechnology Information, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/piv-3/piv+3+sequence+accession+numbers/pmc11036794-67-4-13 Average 90 stars, based on 1 article reviews
piv-3 sequence accession numbers - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
ImmunoGen Inc
pref from rsv, hmpv and piv-3 ![]() Pref From Rsv, Hmpv And Piv 3, supplied by ImmunoGen Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/piv-3/pref+from+rsv++hmpv+and+piv+3/us08889146-819-46-15 Average 90 stars, based on 1 article reviews
pref from rsv, hmpv and piv-3 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Hecin Scientific Inc
piv-3 ![]() Piv 3, supplied by Hecin Scientific Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/piv-3/piv+3/pmc11619282-17-20-0 Average 90 stars, based on 1 article reviews
piv-3 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
MedImmune llc
recombinant human/bovine piv-3 hpiv-3 bovine n genef ![]() Recombinant Human/Bovine Piv 3 Hpiv 3 Bovine N Genef, supplied by MedImmune llc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/piv-3/recombinant+human+bovine+piv+3+hpiv+3+bovine+n+genef/pm14689350-62-61-50 Average 90 stars, based on 1 article reviews
recombinant human/bovine piv-3 hpiv-3 bovine n genef - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
ModernaTX Inc
fusion proteins hmpv piv3 ![]() Fusion Proteins Hmpv Piv3, supplied by ModernaTX Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/piv-3/fusion+proteins+hmpv+piv3/pmc08940982-131-11-0 Average 90 stars, based on 1 article reviews
fusion proteins hmpv piv3 - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
Image Search Results
Journal: The Cochrane Database of Systematic Reviews
Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis
doi: 10.1002/14651858.CD011780.pub2
Figure Lengend Snippet: Equivalent schedules of intradermal fractional‐dose inactivated poliovirus vaccine compared to intramuscular inactivated poliovirus vaccine for the prevention of poliomyelitis in children
Article Snippet: The median
Techniques:
Journal: The Cochrane Database of Systematic Reviews
Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis
doi: 10.1002/14651858.CD011780.pub2
Figure Lengend Snippet: Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 1 Seroconversion rate after a single primary dose: type 1 poliovirus.
Article Snippet: The median
Techniques:
Journal: The Cochrane Database of Systematic Reviews
Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis
doi: 10.1002/14651858.CD011780.pub2
Figure Lengend Snippet: Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 4 Seroconversion rate after 2 primary doses: type 1 poliovirus.
Article Snippet: The median
Techniques:
Journal: The Cochrane Database of Systematic Reviews
Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis
doi: 10.1002/14651858.CD011780.pub2
Figure Lengend Snippet: Comparison 1 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome), Outcome 7 Seroconversion rate after 3 primary doses: type 1 poliovirus.
Article Snippet: The median
Techniques:
Journal: The Cochrane Database of Systematic Reviews
Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis
doi: 10.1002/14651858.CD011780.pub2
Figure Lengend Snippet: Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 1 Seroconversion rate after a single primary dose: type 1 poliovirus.
Article Snippet: The median
Techniques:
Journal: The Cochrane Database of Systematic Reviews
Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis
doi: 10.1002/14651858.CD011780.pub2
Figure Lengend Snippet: Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 4 Seroconversion rate after 2 primary doses: type 1 poliovirus.
Article Snippet: The median
Techniques:
Journal: The Cochrane Database of Systematic Reviews
Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis
doi: 10.1002/14651858.CD011780.pub2
Figure Lengend Snippet: Comparison 2 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome), Outcome 7 Seroconversion rate after 3 primary doses: type 1 poliovirus.
Article Snippet: The median
Techniques:
Journal: The Cochrane Database of Systematic Reviews
Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis
doi: 10.1002/14651858.CD011780.pub2
Figure Lengend Snippet: Geometric titres: children (median titres reported in included studies that could not be used in a meta‐analysis)
Article Snippet: The median
Techniques: Injection
Journal: The Cochrane Database of Systematic Reviews
Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis
doi: 10.1002/14651858.CD011780.pub2
Figure Lengend Snippet: Comparison 3 Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (secondary outcome), Outcome 1 Reciprocal antibody titres: seroprevalence for antipoliovirus antibodies type 1.
Article Snippet: The median
Techniques:
Journal: The Cochrane Database of Systematic Reviews
Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis
doi: 10.1002/14651858.CD011780.pub2
Figure Lengend Snippet: Comparison 4 Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (secondary outcome), Outcome 1 Reciprocal antibody titres: seroprevalence for antipoliovirus antibodies type 1.
Article Snippet: The median
Techniques:
Journal: The Cochrane Database of Systematic Reviews
Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis
doi: 10.1002/14651858.CD011780.pub2
Figure Lengend Snippet: Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (primary outcome)
Article Snippet: The median
Techniques:
Journal: The Cochrane Database of Systematic Reviews
Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis
doi: 10.1002/14651858.CD011780.pub2
Figure Lengend Snippet: Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (primary outcome)
Article Snippet: The median
Techniques:
Journal: The Cochrane Database of Systematic Reviews
Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis
doi: 10.1002/14651858.CD011780.pub2
Figure Lengend Snippet: Intradermal fractional‐dose IPV versus intramuscular IPV: children (random‐effects model) (secondary outcome)
Article Snippet: The median
Techniques:
Journal: The Cochrane Database of Systematic Reviews
Article Title: Equivalent schedules of intradermal fractional dose versus intramuscular full dose of inactivated polio vaccine for prevention of poliomyelitis
doi: 10.1002/14651858.CD011780.pub2
Figure Lengend Snippet: Intradermal fractional‐dose IPV versus intramuscular IPV: children (fixed‐effect model) (secondary outcome)
Article Snippet: The median
Techniques:
Journal: Frontiers in Immunology
Article Title: Bovine Immunology: Implications for Dairy Cattle
doi: 10.3389/fimmu.2021.643206
Figure Lengend Snippet: USDA licensed antiviral and antibacterial vaccines and preventative therapeutic products for cattle.
Article Snippet: BHV-1, BVDV, PIV-3,
Techniques: Vaccines, Virus
Journal: Vaccines
Article Title: Vaccine Development for Human Pneumoviruses
doi: 10.3390/vaccines13060569
Figure Lengend Snippet: Schematic representation of prefusion ( A ) RSV-F (PDB ID: 8W3P) or ( B ) postfusion RSV-F (PDB ID: 3RRT); schematic representation of ( C ) prefusion HMPV-F PDB ID: 7SEJ) or ( D ) postfusion HMPV-F (PDB ID: 7m0i); genome organization of ( E ) HMPV or ( F ) RSV. Created with PyMOL and BioRender.
Article Snippet: - RSV/HMPV/PIV3
Techniques:
Journal: Nature Genetics
Article Title: Genome-wide bidirectional CRISPR screens identify mucins as host factors modulating SARS-CoV-2 infection
doi: 10.1038/s41588-022-01131-x
Figure Lengend Snippet: a – c , Calu-3 mucin GOF cells were infected with ( a ) SARS-CoV-2, ( b ) HKU5-SARS-CoV-S or ( c ) MERS-CoV at an MOI of 0.1. At 24 h postinfection, viral titers were quantified by plaque assay. The dotted line is the NTG average, n = 3 biological replicates. Significance was calculated by a two-sided t -test between each GOF cell line versus NTG. d , As a – c , except on WT Calu-3 cells pretreated with StcE. n = 3 biological replicates, two-sided t -tests were performed for the indicated pairs. e , Calu-3 cells were treated with StcE or left untreated and then infected with the indicated virus for 24 h. Relative levels of viral gene copies were quantified by RT–qPCR. Displayed are n = 4 (HCoV-229E), n = 10 (HCoV-OC43), n = 15 (Influenza A virus, PR8), n = 5 (PIV3) and n = 10 (RSV) biological replicates. Two-sided t -tests were performed for the indicated pairs. f , g . Mucin-overexpressing Calu-3 cells were infected with HCoV-229E or PIV3, and relative levels of viral gene copies were quantified 24 h postinfection by RT–qPCR. n = 3 biological replicates, the dotted line is the NTG average. Significance was calculated by a two-sided t -test between each GOF cell line versus NTG. h , PIV3 infection of the indicated GOF Calu-3 cells, with and without StcE treatment, at 48 h postinfection quantifying GFP + cells. Displayed is a single time point from the experiment shown in Extended Data Fig. . Displayed are n = 5 biological replicates, two-sided t -tests were performed for the indicated pairs. Dotted lines indicate the NTG average for two separate guides, with (upper) and without (lower) StcE treatment. Error bars denote mean ± s.e.m. NS, not significant; * P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001.
Article Snippet: Stocks of
Techniques: Infection, Plaque Assay, Virus, Quantitative RT-PCR
Journal: Nature Genetics
Article Title: Genome-wide bidirectional CRISPR screens identify mucins as host factors modulating SARS-CoV-2 infection
doi: 10.1038/s41588-022-01131-x
Figure Lengend Snippet: a . Incucyte trace tracking GFP + (PIV3 infected) cells over 72 hours in Calu-3 mucin GOF cell lines, either pretreated with StcE or not, n = 5 biological replicates. Full dataset for the 48-hour time point from Fig. . b-c . Plaque assay measuring viral loads of the indicated Calu-3 GOF cells infected with HKU5-SARS-Cov-1, or MERS-CoV, respectively, at 24 hpi at an MOI of 0.1. Dotted line indicates the NTG average for guides tested. Significance was calculated by individual two-sided t-tests comparing each cell line to NTG, n = 3 biological replicates. d-e . qRT-PCR measuring viral gene copies 24 hpi in mucin-overexpressing cell lines for 229E (MOI 0.05), or PIV3 (MOI 0.0002), respectively. Dotted line indicates the NTG average. Significance was calculated by individual two-sided t-tests comparing each cell line to NTG, n = 3 biological replicates. f . GFP + (infected) cells from indicated GOF Calu-3 cell lines infected with PIV3 at MOI 0.0002 at 40 hpi. Significance was calculated by individual two-sided t-tests comparing each cell line to NTG, n = 3 biological replicates. Dotted line indicates the NTG average. g . Incucyte trace tracking GFP + infected cells from (f). For all panels : error bars denote mean ± s.e.m., significance is indicated as: n.s.=not significant, *= P < 0.05, **= P < 0.01, ***=P < 0.001, ****= P < 0.0001.
Article Snippet: Stocks of
Techniques: Infection, Plaque Assay, Quantitative RT-PCR
Journal: Signal Transduction and Targeted Therapy
Article Title: Advances in COVID-19 mRNA vaccine development
doi: 10.1038/s41392-022-00950-y
Figure Lengend Snippet: mRNA vaccine candidates for infectious diseases currently in clinical trials
Article Snippet:
Techniques: